Novel neurofibromatosis type 2 mutation presenting with status epilepticus

Jacopo C. DiFrancesco, Roberta Sestini, Federica Cossu, Martino Bolognesi, Elena Sala, Silvana Mariani, Enrico Saracchi, Laura Papi, Carlo Ferrarese

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Neurofibromatosis type 2 (NF2) is a dominantly inherited syndrome caused by mutations of the tumour-suppressor NF2, which encodes the merlin protein. Mutations are associated with a predisposition to development of benign tumours in the central nervous system. Even though cerebral cortical lesions are frequently associated with seizures, epilepsy is rarely described in NF2. Here, we describe an adult case of NF2 in which the onset of symptoms was characterised by status epilepticus. In this patient, we identified the novel c.428-430delCTTdel mutation in NF2, involving the amino-terminal FERM domain, which is fundamental for the correct tumour suppressor function of the protein. Bioinformatic analyses revealed an important structural perturbation of the FERM domain, with a predicted impairment of the anti-tumour activity.

Original languageEnglish
Pages (from-to)132-137
Number of pages6
JournalEpileptic Disorders
Volume16
Issue number1
DOIs
Publication statusPublished - 2014

Fingerprint

Neurofibromatosis 2
Status Epilepticus
Mutation
Neurofibromin 2
Genetic Suppression
Tumor Suppressor Proteins
Central Nervous System Neoplasms
Computational Biology
Epilepsy
Neoplasms
Seizures
Proteins

Keywords

  • Epilepsy
  • Merlin
  • Neurofibromatosis type 2
  • NF2
  • Novel mutation
  • Status epilepticus

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

DiFrancesco, J. C., Sestini, R., Cossu, F., Bolognesi, M., Sala, E., Mariani, S., ... Ferrarese, C. (2014). Novel neurofibromatosis type 2 mutation presenting with status epilepticus. Epileptic Disorders, 16(1), 132-137. https://doi.org/10.1684/epd.2014.0647

Novel neurofibromatosis type 2 mutation presenting with status epilepticus. / DiFrancesco, Jacopo C.; Sestini, Roberta; Cossu, Federica; Bolognesi, Martino; Sala, Elena; Mariani, Silvana; Saracchi, Enrico; Papi, Laura; Ferrarese, Carlo.

In: Epileptic Disorders, Vol. 16, No. 1, 2014, p. 132-137.

Research output: Contribution to journalArticle

DiFrancesco, JC, Sestini, R, Cossu, F, Bolognesi, M, Sala, E, Mariani, S, Saracchi, E, Papi, L & Ferrarese, C 2014, 'Novel neurofibromatosis type 2 mutation presenting with status epilepticus', Epileptic Disorders, vol. 16, no. 1, pp. 132-137. https://doi.org/10.1684/epd.2014.0647
DiFrancesco JC, Sestini R, Cossu F, Bolognesi M, Sala E, Mariani S et al. Novel neurofibromatosis type 2 mutation presenting with status epilepticus. Epileptic Disorders. 2014;16(1):132-137. https://doi.org/10.1684/epd.2014.0647
DiFrancesco, Jacopo C. ; Sestini, Roberta ; Cossu, Federica ; Bolognesi, Martino ; Sala, Elena ; Mariani, Silvana ; Saracchi, Enrico ; Papi, Laura ; Ferrarese, Carlo. / Novel neurofibromatosis type 2 mutation presenting with status epilepticus. In: Epileptic Disorders. 2014 ; Vol. 16, No. 1. pp. 132-137.
@article{5c40e30588d541239458c973530917e0,
title = "Novel neurofibromatosis type 2 mutation presenting with status epilepticus",
abstract = "Neurofibromatosis type 2 (NF2) is a dominantly inherited syndrome caused by mutations of the tumour-suppressor NF2, which encodes the merlin protein. Mutations are associated with a predisposition to development of benign tumours in the central nervous system. Even though cerebral cortical lesions are frequently associated with seizures, epilepsy is rarely described in NF2. Here, we describe an adult case of NF2 in which the onset of symptoms was characterised by status epilepticus. In this patient, we identified the novel c.428-430delCTTdel mutation in NF2, involving the amino-terminal FERM domain, which is fundamental for the correct tumour suppressor function of the protein. Bioinformatic analyses revealed an important structural perturbation of the FERM domain, with a predicted impairment of the anti-tumour activity.",
keywords = "Epilepsy, Merlin, Neurofibromatosis type 2, NF2, Novel mutation, Status epilepticus",
author = "DiFrancesco, {Jacopo C.} and Roberta Sestini and Federica Cossu and Martino Bolognesi and Elena Sala and Silvana Mariani and Enrico Saracchi and Laura Papi and Carlo Ferrarese",
year = "2014",
doi = "10.1684/epd.2014.0647",
language = "English",
volume = "16",
pages = "132--137",
journal = "Epileptic Disorders",
issn = "1294-9361",
publisher = "Springer Paris",
number = "1",

}

TY - JOUR

T1 - Novel neurofibromatosis type 2 mutation presenting with status epilepticus

AU - DiFrancesco, Jacopo C.

AU - Sestini, Roberta

AU - Cossu, Federica

AU - Bolognesi, Martino

AU - Sala, Elena

AU - Mariani, Silvana

AU - Saracchi, Enrico

AU - Papi, Laura

AU - Ferrarese, Carlo

PY - 2014

Y1 - 2014

N2 - Neurofibromatosis type 2 (NF2) is a dominantly inherited syndrome caused by mutations of the tumour-suppressor NF2, which encodes the merlin protein. Mutations are associated with a predisposition to development of benign tumours in the central nervous system. Even though cerebral cortical lesions are frequently associated with seizures, epilepsy is rarely described in NF2. Here, we describe an adult case of NF2 in which the onset of symptoms was characterised by status epilepticus. In this patient, we identified the novel c.428-430delCTTdel mutation in NF2, involving the amino-terminal FERM domain, which is fundamental for the correct tumour suppressor function of the protein. Bioinformatic analyses revealed an important structural perturbation of the FERM domain, with a predicted impairment of the anti-tumour activity.

AB - Neurofibromatosis type 2 (NF2) is a dominantly inherited syndrome caused by mutations of the tumour-suppressor NF2, which encodes the merlin protein. Mutations are associated with a predisposition to development of benign tumours in the central nervous system. Even though cerebral cortical lesions are frequently associated with seizures, epilepsy is rarely described in NF2. Here, we describe an adult case of NF2 in which the onset of symptoms was characterised by status epilepticus. In this patient, we identified the novel c.428-430delCTTdel mutation in NF2, involving the amino-terminal FERM domain, which is fundamental for the correct tumour suppressor function of the protein. Bioinformatic analyses revealed an important structural perturbation of the FERM domain, with a predicted impairment of the anti-tumour activity.

KW - Epilepsy

KW - Merlin

KW - Neurofibromatosis type 2

KW - NF2

KW - Novel mutation

KW - Status epilepticus

UR - http://www.scopus.com/inward/record.url?scp=84898739117&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898739117&partnerID=8YFLogxK

U2 - 10.1684/epd.2014.0647

DO - 10.1684/epd.2014.0647

M3 - Article

C2 - 24667735

AN - SCOPUS:84898739117

VL - 16

SP - 132

EP - 137

JO - Epileptic Disorders

JF - Epileptic Disorders

SN - 1294-9361

IS - 1

ER -